| Autor: |
Wang X; Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China., Xie JZ; Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China., Long ZC; Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China., Li JH; Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China., Hao YT; Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China Center of Global Health Research, Sun Yat-sen University, Guangzhou 510080, China Center for Health Information Research, Sun Yat-sen University, Guangzhou 510300, China Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China., Jie YS; Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China., Gu J; Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China Center of Global Health Research, Sun Yat-sen University, Guangzhou 510080, China Center for Health Information Research, Sun Yat-sen University, Guangzhou 510300, China. |
| Abstrakt: |
With the increasing life expectancy and lifestyle changes of patients with chronic hepatitis B (CHB), the significance of comorbidities of chronic non-communicable diseases (NCDs) in disease progression and health prognosis of CHB patients is gaining prominence. This study aims to explore the association between CHB and NCDs comorbidities, focusing on the impact of common metabolism-related diseases, such as metabolic syndrome and diabetes, on the health outcomes of CHB patients. We also summarize studies on integrating the management of comorbidities in CHB patients and provide relevant recommendations for effective management. The findings of this study serve as a foundation for understanding the clinical characteristics and prevalence trends, reducing the disease burden of comorbidities among CHB patients, and establishing a comprehensive and coordinated management system for comorbidities. |
